CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Travoprost 0.004%/timolol maleate 0.5% fixed combinationdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01336569
NCT01336569Phase 4Completed
CompareCT.gov

Safety and Efficacy of Using the Travoprost/Timolol Fixed Combination (DuoTrav®) in Patients With Open-Angle Glaucoma or Uncontrolled Ocular Hypertension by Beta-blocker Monotherapy (Timolol 0.5%)

Alcon Research·interventional·Posted Apr 18, 2011·Updated Jul 8, 2013

In Brief

A Phase 4 clinical trial evaluating Travoprost 0.004%/timolol maleate 0.5% fixed combination for Glaucoma. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 18, 2011
Enrollment StartFeb 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.2 years ago

Interventions

Travoprost 0.004%/timolol maleate 0.5% fixed combinationdrug